Skip to main content
OpenTrials
Completed

NCT Number: NCT01771627

Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers

This pilot clinical trial studies varenicline or nicotine patch in promoting smoking cessation among current smokers. Varenicline or nicotine patch may help people stop smoking

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Roswell Park Cancer Institute

Buffalo, New York, 14263, United States

About this study

PRIMARY OBJECTIVES:

I. To determine if mail delivery of 12 weeks of varenicline results in improved smoking cessation outcomes relative to nicotine replacement therapy (NRT) in 300 smokers.

II. To determine if delivery of varenicline is cost-effective as compared to nicotine patch.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients undergo general smoking cessation counseling and receive varenicline orally (PO) twice daily (QD) on days 1-28. Courses repeat every 28 days for up to 12 weeks.

ARM II: Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.

After completion of study treatment, patients are followed up at 4 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cigarette smokers who call the New York State Smokers' Quitline requesting assistance with quitting smoking
  • State that they are under the care of a primary care physician
  • Are eligible for receipt of pharmacotherapy by mail using the standard NRT criteria
  • Speak English
  • Answer "no" to the following 3 questions:
  • "Have you ever been diagnosed with or treated for a mental health problem like major depression, bipolar disorder, dysthymia, or schizoaffective disorder?"
  • "Have you ever had serious thoughts of killing or hurting yourself, ever have any intention or plan to carry out these thoughts, or actually attempted to kill yourself?"
  • "Is there any reason that you cannot use varenicline/Chantix?"

Exclusion criteria

  • State that they are not under the care of a primary care physician
  • Are not eligible for receipt of pharmacotherapy by mail using the standard NRT criteria
  • Do not speak English
  • Answer "yes" to the question, "have you ever been diagnosed with or treated for a mental health problem like major depression, bipolar disorder, dysthymia, or schizoaffective disorder?"
  • Answer "yes" to the question, "have you ever had serious thoughts of killing or hurting yourself, ever have any intention or plan to carry out these thoughts, or actually attempted to kill yourself?"
  • Answer "yes" to the question, "is there any reason that you cannot use varenicline/Chantix?"
  • Are women who are currently pregnant
  • Report that they are unwilling to receive or take varenicline on screening

Treatment and study plan

Varenicline

Drug

Given PO

Other names: Champix, Chantix, CP-526555

Nicotine patch

Drug

Other names: NicoDerm CQ, nicotine skin patch, nicotine transdermal patch, nicotine transdermal system patch

Primary outcomes

  1. Quit Rate

    Time frame: 4 months

    The quit rate at 4 months will be compared between the 2 groups, using a logistic regression analysis with a 2-side 95% confidence interval.

Sponsors and collaborators

Lead sponsor

Roswell Park Cancer Institute

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Pilot Study of Varenicline vs. Nicotine Patch Delivered by a Telephone Quitline to Promote Smoking Cessation

Important dates

Study start
2012
Primary completion
2014
Study completion
2015
First posted
Jan 18, 2013
Registry last updated
Sep 28, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.